Department of Medical Microbiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18 Street, 40-752, Katowice, Poland.
Med Holding Emil Michalowski Specialist Hospital, Katowice, Poland.
Braz J Microbiol. 2021 Dec;52(4):2013-2019. doi: 10.1007/s42770-021-00620-1. Epub 2021 Sep 24.
Many serious and fatal infections with urogenital mycoplasmas in immunocompromised patients have been reported. M. genitalium is recognized as a cause of male urethritis and other common genitourinary diseases. The aim of the study was to estimate prevalence of urogenital mycoplasmas which can cause complications in men with common genitourinary diseases. Study included 85 men with genitourinary tract carcinoma (n = 35), urolithiasis (n = 36), and BPH (benign prostatic hyperplasia) (n = 14). The control group consisted of 50 healthy men. FVU (first void urine) samples were examined by PCR for the presence of urogenital mycoplasmas DNA. Occurrence of urogenital mycoplasmas was significantly more common in study group compared with control 24/85 (28.2%) and 7/50 (14%), respectively (p = 0.05). In men with urolithiasis, positive results for mycoplasmas DNA were significantly more frequent than in control: 33.3% vs. 14% (p < 0.05). In patients with urolithiasis DNA of U. urealyticum was most often found, while in the genitourinary carcinoma and BPH groups, U. parvum was more frequent. Incidence of M. fermentans was also significantly higher in the urolithiasis group vs. control (p = 0.03). A higher percentage of positive results for urogenital mycoplasma DNA in study group has been found. Further studies are required to confirm the role of urogenital mycoplasmas in the development of infectious complications among patients with urolithiasis, genitourinary carcinoma, and BPH.
许多免疫功能低下患者的泌尿生殖道支原体严重和致命感染已有报道。生殖支原体被认为是男性尿道炎和其他常见泌尿生殖道疾病的病因。本研究旨在评估可能导致男性常见泌尿生殖道疾病并发症的泌尿生殖道支原体的流行率。研究纳入了 85 名患有泌尿生殖道癌（n=35）、尿路结石（n=36）和良性前列腺增生（BPH）（n=14）的男性患者。对照组由 50 名健康男性组成。采用 PCR 检测 FVU（首次排尿）样本中泌尿生殖道支原体 DNA 的存在。与对照组相比，研究组泌尿生殖道支原体的发生率明显更高，分别为 24/85（28.2%）和 7/50（14%）（p=0.05）。在尿路结石患者中，支原体 DNA 阳性结果明显高于对照组：33.3%比 14%（p<0.05）。在尿路结石和 BPH 组中，最常发现 U. urealyticum 的 DNA，而在泌尿生殖道癌组中，U. parvum 更为常见。在尿路结石组中，M. fermentans 的发生率也明显高于对照组（p=0.03）。研究组中泌尿生殖道支原体 DNA 阳性结果的比例较高。需要进一步的研究来证实泌尿生殖道支原体在尿路结石、泌尿生殖道癌和 BPH 患者感染性并发症发展中的作用。
